APA (7th ed.) Citation

Ness, D. B., Hourdequin, K. C., Ripple, G. H., Amin, M. A., Lord-Halvorson, S., Khan, W. A., . . . Lewis, L. D. (2024). Association of plasma uracil concentration with 5-FU pharmacokinetics, dose-limiting toxicity, and DPYD genotype in patients with gastrointestinal cancer. Journal of clinical oncology, 42(3_suppl), 751. https://doi.org/10.1200/JCO.2024.42.3_suppl.751

Chicago Style (17th ed.) Citation

Ness, Dylan B., et al. "Association of Plasma Uracil Concentration with 5-FU Pharmacokinetics, Dose-limiting Toxicity, and DPYD Genotype in Patients with Gastrointestinal Cancer." Journal of Clinical Oncology 42, no. 3_suppl (2024): 751. https://doi.org/10.1200/JCO.2024.42.3_suppl.751.

MLA (9th ed.) Citation

Ness, Dylan B., et al. "Association of Plasma Uracil Concentration with 5-FU Pharmacokinetics, Dose-limiting Toxicity, and DPYD Genotype in Patients with Gastrointestinal Cancer." Journal of Clinical Oncology, vol. 42, no. 3_suppl, 2024, p. 751, https://doi.org/10.1200/JCO.2024.42.3_suppl.751.